RE:RE:RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs The pharmaceutical product industry is India's most advantageous industry, and it is also an industry with which India hoped to strengthen cooperation with China. In the context of “One Belt, One Road,” China–India pharmaceutical industry cooperation sought to gain global dominance over the pharmaceutical industry, and in so doing, take control of the drug therapeutics industry in the United States. The US Federal Government is using its power through the enactment of IRA to preclude this foreign-agent dominance from happening in the United States by providing real incentives to companies who choose to develop and market large molecule biological drug therapies, that are difficult to copy and manufacture, and which will make the United States the global powerhouse in the creation, development and manufacture of next-generation drug therapeutics (i.e. immunotherapies), which will treat some of the most difficult diseases that currently have unmet treatment needs - ([ike for example ONCY's drug platform pelareorep which is reaching the Phase 3 clinical development / drug registration / approval stage for the treatment of multiple cancers (including rare /orphan diseases) with unmet treatment needs].